

### Exhaled nitric oxide receives reimbursement in Europe

Health care providers using exhaled nitric oxide (eNO) will receive payment in Portugal (code 95460) and Finland (code 4812) from the respective healthcare systems. The implications of reimbursement result in the physician's ability to use eNO more routinely to more accurately diagnosis asthmatics and to monitor the control of their asthma symptoms.

A cornerstone in asthma treatment is the use of anti-inflammatory therapy, such as inhaled corticosteroids. Exhaled nitric oxide values can be used to monitor the effects of treatment; a rise in the eNO value may indicate that the patient is not completely following the prescribed anti-inflammatory treatment or that the disease is worsening. By monitoring eNO, there is an improvement in the management and care of asthmatic patients. This improvement leads to a cost effective asthma management.

Aerocrine's NIOX MINO<sup>®</sup> Airway Inflammation Monitor permits non-invasive, quick and easy to perform eNO measurements. The pre-calibrated NO sensor assures accurate, repeatable and reproducible results that correlate and agree well with those from Aerocrine's stationary NIOX<sup>®</sup> exhaled NO monitoring system.

Aerocrine AB is a clinically based medical technology company. A leader in the development of devices for monitoring inflammation, Aerocrine is dedicated to improving the management and care of patients by measuring airborne markers, primarily nitric oxide (NO).

Teprel and Spira are Aerocrine distribution partners in Portugal and Finland, respectively.

For more information, please contact:

Lena Kajland-Wilén, Director of Marketing, Aerocrine AB, +46 70 629 0784 Thomas Almesjö, President & CEO, Aerocrine AB, +46 70 629 0782 Jose Pereira, Comercial Director, Teprel- Equipamentos Médicos, Lda, +351 229 999 880 Pertti Seitsonen, Sales Director, Spira Respiratory Care Center Ltd, +358 3 6280 929	3 November 2006
--	-----------------